Role of Bradykinin in Protection of Ischemic Preconditioning in Rabbit Hearts

Author:

Goto Mahiko1,Liu Yongge1,Yang Xi-Ming1,Ardell Jeffrey L.1,Cohen Michael V.1,Downey James M.1

Affiliation:

1. From the Departments of Medicine (M.V.C.) and Physiology, University of South Alabama, College of Medicine, Mobile.

Abstract

Abstract Bradykinin receptor activation has been proposed to be involved in ischemic preconditioning. In the present study, we further investigated the role of this agent in preconditioning in both isolated and in situ rabbit hearts. All hearts were subjected to 30 minutes of regional ischemia followed by reperfusion for 2 hours (in vitro hearts) and 3 hours (in situ hearts). Infarct size was measured by tetrazolium staining and expressed as a percentage of the size of the risk zone. Preconditioning in situ hearts with 5 minutes of ischemia and 10 minutes of reperfusion significantly reduced infarct size to 10.2±2.2% of the risk region ( P <.0005 versus control infarct size of 36.7±2.6%). Pretreatment with HOE 140 (26 μg/kg), a bradykinin B 2 receptor blocker, did not alter infarct size in nonpreconditioned hearts (40.6±5.3% infarction) but abolished protection from ischemic preconditioning (34.1±1.6% infarction). However, when HOE 140 was administered during the initial reflow period following 5 minutes of ischemia, protection was no longer abolished (15.6±3.9% infarction versus 13.3±3.8% without HOE 140, P =NS). Bradykinin infusion in isolated hearts mimicked preconditioning, and protection was not affected by pretreatment with the nitric oxide synthase inhibitor N ω -nitro- l -arginine methyl ester or the prostaglandin synthesis inhibitor indomethacin but could be completely abolished by the protein kinase C (PKC) inhibitors polymyxin B and staurosporine as well as by HOE 140. HOE 140 could not block the protection of ischemic preconditioning in isolated hearts. That failure was apparently due to the absence of blood-borne kininogens rather than autonomic nerves. When the preconditioning stimulus in the in situ model was amplified with four cycles of 5-minute ischemia/10-minute reperfusion, HOE 140 pretreatment could no longer block protection (infarct size was 10.7±3.5% versus 6.4±2.0% without HOE 140, P =NS). We propose that bradykinin receptors protect by coupling to PKC as do adenosine receptors, and blockade of either receptor will diminish the total stimulus of PKC below threshold and prevent protection. A more intense preconditioning ischemic stimulus can overcome bradykinin receptor blockade, however, by simply enhancing the amount of adenosine and possibly other agonists released.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Physiology

Reference71 articles.

1. Interstitial purine metabolites during regional myocardial ischemia

2. Schömig A. Catecholamines in myocardial ischemia: systemic and cardiac release. Circulation . 1990;82(suppl II):II-13-II-22.

3. Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs

Cited by 473 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3